Search results
Results From The WOW.Com Content Network
Immunofluorescence pattern of SS-A and SS-B antibodies. Produced using serum from a patient on HEp-20-10 cells with a FITC conjugate. Anti-SSA autoantibodies (anti–Sjögren's-syndrome-related antigen A autoantibodies, also called anti-Ro, or similar names including anti-SSA/Ro, anti-Ro/SSA, anti–SS-A/Ro, and anti-Ro/SS-A) are a type of anti-nuclear autoantibodies that are associated with ...
20823 Ensembl ENSG00000138385 ENSMUSG00000068882 UniProt P05455 P32067 RefSeq (mRNA) NM_003142 NM_001294145 NM_001110145 NM_009278 NM_001355265 RefSeq (protein) NP_001281074 NP_003133 NP_001103615 NP_033304 NP_001342194 Location (UCSC) Chr 2: 169.79 – 169.81 Mb Chr 2: 69.69 – 69.7 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Sjögren syndrome type B antigen (SS-B) also known ...
Indeed, in 84.3% of positive anti-ENA samples, ANA reagents were also found. [1] The use of anti-ENA autoantibody tests can serve as additional verification of an autoimmune disorder, because a positive ANA test alone does not suffice for diagnosis. In fact, low levels of ANAs can be found in healthy patients.
Anti-Scl-70 (also called anti-topoisomerase I after the type I topoisomerase target [1]) is an anti-topoisomerase antibody-type of anti-nuclear autoantibodies, seen mainly in diffuse systemic scleroderma (with a sensitivity of 28–70%), but is also seen in 10–18% of cases of the more limited form of systemic scleroderma called CREST syndrome. [2]
The idea behind the "mixed" disease is that this specific autoantibody is also present in other autoimmune diseases such as systemic lupus erythematosus, polymyositis, scleroderma, etc. MCTD was characterized as an individual disease in 1972 by Sharp et al., [3] [4] and the term was introduced by Leroy [5] in 1980. [6]
AOL latest headlines, entertainment, sports, articles for business, health and world news.
Anti-centromere antibodies (ACAs; often styled solid, anticentromere) are autoantibodies specific to centromere and kinetochore function. They occur in some autoimmune diseases , frequently in limited systemic scleroderma (formerly called CREST syndrome ), and occasionally in the diffuse form of scleroderma .
Idiopathic multicentric Castleman disease (iMCD) is a subtype of Castleman disease (also known as giant lymph node hyperplasia, lymphoid hamartoma, or angiofollicular lymph node hyperplasia), a group of lymphoproliferative disorders characterized by lymph node enlargement, characteristic features on microscopic analysis of enlarged lymph node tissue, and a range of symptoms and clinical findings.